Kornimate/medical-research-clean huggingface dataset:
immunomodulatory effects of silymarin in patients with beta-thalassemia major

Conditions: Immune Abnormalities

Summary: a wide spectrum of immune abnormalities has been described by numerous studies involving β-thalassemic patients with multiple transfusions. the abnormalities observed are both quantitative and functional, and concern several components of the immune response. flavonoids are phenolic compounds widely distributed in plants, which were reported to exert multiple biological effects, including antioxidant and free radical scavenging abilities. silymarin, a flavonolignan complex isolated from milk thistle (silybum marianum l. gaertn), have been classified as cytoprotective, antioxidant, anti-inflammatory, and especially as hepatoprotective agents. silymarin is already being used clinically for treatment of liver diseases.it is considered safe and well-tolerated, with reported adverse events similar to placebo. several studies have also reported immunomodulatory actions of silymarin. it increases lymphocyte proliferation, interferon gamma, interleukin (il)-4 and il-10 secretions by stimulated lymphocytes in a dose-dependent manner. it has been shown that in vitro treatment of peripheral blood mononuclear cells with silymarin causes restoration of the thiol status and increases in t cell proliferation and activation. because reactive oxygen species and iron overload play important roles in the pathophysiology of thalassemia, silymarin may be an effective therapy due to its antioxidant, immunomodulatory, cytoprotective and iron chelating activities. the present study designed to investigate the therapeutic activity of orally administered silymarin for treatment of β-thalassemia major, a well-known and prevalent disease in iran, which is associated with oxidative stress, iron overload and immune abnormalities.


Eligibility criteria:
inclusion criteria: * homozygous beta-thalassemia major * regularly blood transfusion * iron chelation therapy with subcutaneous desferrioxamine (dfo)40.0 mg/kg/day for 5-7 days/week exclusion criteria: * chronic hepatitis b infection * active hepatitis c infection * a history of a positive hiv test * chronic renal or heart failure * iron chelation therapy with deferiprone * pregnancy * gastrointestinal conditions preventing absorption of an oral medication o * noncompliance with prescribed therapy

Keywords: focus immunomodulatory effect of silymarin on cell mediated immunity beta-thalassemia major patients.
a study to learn about tafamidis in patients with transthyretin amyloid cardiomyopathy (attr-cm) in india

Conditions: Transthyretin Amyloid Cardiomyopathy

Summary: the purpose of this study is to learn about the safety of tafamidis for the treatment of transthyretin amyloid cardiomyopathy (attr-cm) in india. attr-cm is a condition that affects people's hearts. transthyretin is a protein that is made in the liver. in some people this protein stops working and forms clumps called as amyloid. transthyretin amyloid builds up in heart and stops the heart from pumping properly. this study is seeking for participants who are: * confirmed with attr-cm. * given tafamidis capsules to be taken by mouth. the safety of tafamidis capsules will be checked based on side effects. these side effects can happen within 6 months after taking tafamidis. a side effect is something (expected or unexpected) that you feel was caused by a medicine or treatment you take. the study doctor will collect side effect information and put the information on patient's case form. follow-up of the patient's will be performed via clinic re-visit or over a call. it is not a rule for the participants to visit the clinic in this study. this study will help to see if tafamidis is safe.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) with diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm). * patients to whom vyndamx® capsules is prescribed for the treatment of wild or hereditary attr-cm. exclusion criteria: * patient with hypersensitivity to vyndamx® capsule or to any of the excipients in the product. * patients with rare hereditary problems of fructose intolerance. * patient who has a contraindication to vyndamx® capsules according to the approved local product label.

Keywords: safety surveillance tafamidis
immunological markers screening for colorectal cancer

Conditions: Colorectal Cancer

Summary: colorectal cancer incidence is increasing at an alarming rate in china. recent reports concluded aberrant immunological function was associated with colorectal cancer outcome, however, the influence of immunocyte subgroup and immunologic factors on cancer outcome in colorectal cancer survivors is largely unknown.the investigators will explore the impact of immunocyte subgroup and immunologic factors on colorectal cancer disease-specific, disease-free and overall survival. the investigators will recruit approximately 5,000 patients as a prospective study cohort. during follow up, the investigators will explore the association of these factors with outcome of patients. the investigators believe that this project will improve the understanding of the impact of immunocyte subgroup and immunologic factors on colorectal cancer outcome.


Eligibility criteria:
inclusion criteria: patient must have a histologically proven adenocarcinoma of colon or rectum cancer. * patients must have a performance status of 0,1, or 2 by the southwest oncology group criteria. * patients must have recovered from any effects of surgery. * evaluable disease must be present outside radiation field. at least 3 weeks must have elapsed after discontinuation of radiation therapy. * patients must provide a signed consent to participate in the study. * patients must complete all questionnaires. exclusion criteria: patients with a proven history of peptic ulcer disease or gastroesophageal reflux. * history of other malignancy, except for cancers that have been treated with a curative intent and patient is without evidence of active disease. * unresolved bacterial infection requiring treatment with antibiotics. * pregnant or lactating women may not participate in the study. * patients known to have hiv-1 virus infection because of the undetermined effect of this chemotherapy regimen in patients with hiv-1 and the potential for serious interaction with anti-hiv medications. * gilbert's disease. * other serious concurrent infection * clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.
a study of dfrf4539a in patients with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this multicenter, open-label, dose-escalating study will assess the safety and efficacy of dfrf4539a in patients with relapsed or refractory multiple myeloma. cohorts of patients will receive multiple ascending doses of intravenous dfrf4539a every 3 weeks or weekly. patients exhibiting acceptable safety and evidence of clinical benefit may receive dfrf4539a for up to 17 cycles. anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients; \>/= 18 years of age * eastern cooperative oncology group (ecog) performance status 0, 1, or 2 * relapsed or refractory multiple myeloma for which no effective standard therapy exists * one of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug * measurable disease as defined by protocol exclusion criteria: * prior use of monoclonal antibody within 4 weeks before cycle 1, day 1 * treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to cycle 1, day 1 * toxicities from any previous treatment must be resolved prior to cycle 1, day 1, except for neuropathy * completion of autologous stem cell transplant within 100 days prior to cycle 1, day 1 * prior allogeneic stem cell transplant * history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) * grade \> 1 peripheral neuropathy * active infection at screening or any major episode of infection requiring treatment with iv antibiotics or hospitalization within 4 weeks prior to cycle 1, day 1 * positive for hepatitis b, hepatitis c or hiv infection * pregnant or lactating women or women who intend to become pregnant within the period of time of this study
short-term effectiveness of transcutaneous nerve stimulation in reducing migraine related pain

Conditions: Headache, Migraine

Summary: the purpose of this study is to evaluate the short-term effectiveness of combined occipital and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.


Eligibility criteria:
inclusion criteria: * subjects with confirmed diagnosis of migraine headache without aura or with typical migraine with aura (ichd-ii code 1.2.1 or 1.1). * subjects with 1-6 migraine episodes per month in the last 2 months. * the subject is capable of understanding the study and to sign an informed consent. exclusion criteria: * subjects who have concomitant epilepsy. * history of neurosurgical interventions. * subjects with metal implants or shrapnel in their head, except for dental implants. * subjects with implanted cardiac pacemaker, neurostimulators, surgical clips (above the shoulder line) or any medical pumps. * history of drug abuse or alcoholism. * history of medications overuse headache. * participation in current clinical study or participated in a clinical study within 3 months prior to this study. * skin lesion or inflammation at the region of the stimulating electrodes. * personality or somatoform disorder. * pregnancy or lactation. * women of reproductive age not using efficient contraceptive method. * history of cerebrovascular event.
monteris autolitt™ fim safety trial for recurrent/progressive brain tumors

Conditions: Brain Tumor; Brain Tumor, Recurrent; Brain Neoplasm; Brain Cancer; Glioblastoma Multiforme; Recurrent Glioblastoma Multiforme

Summary: the main purpose of this study is to evaluate the safety and performance of the autolitt system for the treatment of recurrent/progressive glioblastoma multiforme tumors (gbm).


Eligibility criteria:
inclusion criteria: * previous diagnosis of gbm treated with radiotherapy with or without surgical resection and/or chemotherapy * clinical/radiographic suspicion of tumor recurrence/progression exclusion criteria: * previous treatment of target gbm with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (gliadel).

Keywords: laser interstitial thermal therapy laser therapy thermal therapy brain tumors recurrent brain tumor progressive brain tumor glioblastoma multiforme tumor
a comparison of early mobilization versus traditional treatment for acute ankle sprains.

Conditions: Ankle Sprain

Summary: acute ankle sprain is one of the most common musculoskeletal injuries, accounting for an estimated 2 million injuries per year and 20% of all sports injuries in the united states. ankle sprains can lead to prolonged periods of pain, difficulty with mobility, and lost work or play time. current best practice guidelines for treatment of an acute ankle sprain are protection, rest, ice, compression and elevation (price). however recent systematic reviews for ankle sprains call into question this treatment. two critical components; immobilization and ice, have little or no evidence of efficacy for ankle sprain. interestingly, mobilization appears to be more effective at reducing the pain, swelling and stiffness of musculoskeletal injuries including ankle sprains. historically the limitation to early mobilization has been pain. recently developed stretch bands have been introduced to the therapy market as a tool that allows pain-free active and resisted ankle movement after acute ankle sprain. the investigators propose a double blind randomized controlled study to compare 2 ankle sprain treatments on their ability to speed recovery and reduce morbidities such as pain, swelling and weakness.


Eligibility criteria:
inclusion criteria: * 3 day post injury exclusion criteria: * fracture * chronic sprain

Keywords: acute ankle sprain in children and young adults
teicoplanin in treating septicemia in patients who are receiving chemotherapy through a central venous catheter

Conditions: Infection

Summary: rationale: giving the antibiotic teicoplanin by infusion and allowing bacteria to be exposed to the antibiotic for a longer period of time may be effective in preventing or controlling septicemia. purpose: randomized clinical trial to compare two different methods of giving teicoplanin in treating septicemia in patients who are receiving chemotherapy through a central venous catheter.

objectives: * compare the response and cure rate of coagulase-negative staphylococcal septicemia in patients receiving chemotherapy through a central venous catheter treated with 2 different schedules of teicoplanin. outline: this is a randomized, multicenter study. patients are stratified according to participating center and number of central venous catheter lumens (1 vs 2). patients are randomized to one of two treatment arms. * arm i: patients receive teicoplanin iv bolus every 12 hours for 3 doses and then once daily for 5 doses (total of 7 days). * arm ii: patients receive teicoplanin iv over 2 hours and/or by antibiotic lock every 12 hours for 3 doses and then once daily for 5 doses (total of 7 days). projected accrual: approximately 490-1,360 patients will be accrued for this study within 2.2-6.2 years.

Eligibility criteria:
disease characteristics: * suspected septicemia caused by coagulase-negative staphylococci * single or double lumen (no triple lumen) central venous catheter (cvc) (including subcutaneous ports) that can be flushed and aspirated * expected to remain in situ for at least 8 weeks * no coagulase-negative septicemia associated with existing cvc within the past 12 weeks * receiving chemotherapy for neoplastic condition, aplastic anemia, fanconi's anemia, langerhans' cell histiocytosis, or myelodysplasia patient characteristics: age: * 2 months and over performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * creatinine clearance at least 60 ml/min prior concurrent therapy: biologic therapy * not specified chemotherapy * see disease characteristics endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: infection
comparative effects of bbt and active cycle of breathing technique on dyspnea and quality of life in copd

Conditions: COPD

Summary: comparative effects of butyeko breathing technique and active cycle of breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease

a comparative study to determine the effects of butyeko breathing techniques and active cycle of breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease. as few researches on butyeko breathing techniques are still present on copd most of them are on asthma. the goal of the butyeko method is to improve breathing patterns, as indicated by achieving a higher breath hold time (control pause). every five seconds improvement to the control pause, results in an alleviation of breathing difficulty and improved control of copd the butyeko method is a purported method of "retraining" the body's breathing pattern to correct for the presumed chronic hyperventilation and hypocapnea, and thereby treat or cure the body of these medical problems. patients with chronic obstructive pulmonary disease (copd) often suffer from expectoration. to address this problem, active cycle of breathing techniques (acbt) can be applied in patients of copd. in our study daily butyeko breathing exercise and active cycle of breathing technique session of 30 to 35 minutes will be given to patients and effects of both techniques will be compared. a randomized clinical trial will be conducted using convenient sampling or randomized sampling technique in population of chronic obstructive pulmonary disease (copd).total sample size will be of 40 and two groups will be made group a 20 participants received buyteko breathing technique and groups b 20 participants received active cycle of breathing technique. data will be collected by using borg's dyspnea scale, st.george respiratory questionnaire and by pulmonary function testing. data will be collected from pulmonary ward jinnah hospital lahore whole study will take total duration of 10 months and data will be analyzed using latest version of spss-25 software.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd confirmed by smoking history. * pft showing irreversible airflow limitation. * patients hemodynamically stable. * males and females. * patients capable of completing ipaq questionnaire exclusion criteria: * evidence of unstable cardiac disease, pulmonale decompensation * disabling diseases which prevented participation in the exercise program, such as orthopedic inabilities or peripheral vascular disease. * systemic illness. * resting o2 saturation \<90% with room air breathing and patient with viral infection

Keywords: buteyko breathing technique
correlation of trans cranial doppler ultrasound and ct scan in monitoring of posttraumatic brain edema

Conditions: Brain Edema

Summary: the most common tool for diagnosis and follow up of cerebral edema in icu is brain ct scan that necessitate patient transportation with risk of hemodynamic instability, and exposure to radiation. transcranial doppler (tcd) sonography allows true and rapid imaging of blood flow velocities of intracranial vessels. transcranial doppler sonography provides noninvasive evaluation of intracranial pressure by its characteristic wave patterns


Eligibility criteria:
inclusion criteria: * isolated blunt traumatic brain injury * age 18-60 years exclusion criteria: * pregnancy * intracerebral hemorrhage * patients whose blood flow velocities could not be obtained from trans temporal acoustic bone windows.
levodopa-carbidopa intestinal gel open-label study in advanced parkinson's disease

Conditions: Advanced Parkinson's Disease

Summary: the primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (duodopa®) over 12-months in participants with advanced parkinson's disease (pd) and severe motor fluctuations.

the study was composed of a screening period followed by 3 sequential on-treatment periods, as follows: * screening period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (lc-oral) prior to nasojejunal (nj) tube placement. * nj test period (2 to 14 days): first hospitalization period, baseline assessments, placement of nj tube, and optimization of levodopa-carbidopa intestinal gel (lcig) treatment via nj tube and infusion pump (participant was hospitalized for nj tube placement but hospitalization was not required for entire duration of lcig treatment optimization). * peg-j period (2 to 14 days): second hospitalization period; placement of peg-j tube; further optimization of lcig treatment. * post peg-j long-term treatment period (day 28 to day 378): lcig administration via a permanent peg-j tube and infusion pump, with dosage adjusted according to clinical condition.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease (pd) according to united kingdom parkinson's disease society (ukpds) brain bank criteria * levodopa-responsive with severe motor fluctuations * recognizable off and on state (motor fluctuations) confirmed by diary exclusion criteria: * diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism * undergone surgery for the treatment of pd * contraindications to levodopa (such as narrow angle glaucoma)

Keywords: severe motor fluctuations levodopa levodopa/carbidopa intestinal gel efficacy dyskinesia parkinson's disease carbidopa duopa
effects of robot-assisted arm training on respiratory muscle strength, activities of daily living and quality of life in stroke patients: a single-blinded randomized controlled trial

Conditions: Stroke

Summary: stroke is the leading neurological disease in the world that causes long-term disability. the most common cause of disability after stroke is motor impairment resulting from brain damage which ultimately cause respiratory and functional limitation. respiratory muscle weakness including the diaphragm leads to biomechanical change in respiration which can reduce vital capacity and total lung capacity of stroke patients. the weakness of diaphragm and abdominal muscle also leads to decrease in maximal inspiratory pressure (mip) and maximal expiratory pressure (mep) in stroke patients. respiratory muscle training such as inspiratory or expiratory muscle training is commonly used to improve the respiratory muscle strength and function in stroke. however, it was reported that respiration is closely related to upper limb function because the muscle of upper extremities surrounds the dorsal muscle of trunk and in order to breath, the movement of trunk is necessary, which in turn is related to the movement of the upper limbs.


Eligibility criteria:
inclusion criteria: 1. 18 year and above 2. acute and sub-acute stroke patients 3. had mip values lower than 70% of those predicted when adjusted for age and sex, 4. had no facial palsy, aphasia, or dysarthria, which would prevent respiratory muscle strength testing 5. ischemic or hemorrhagic stroke 6. no medical history of respiratory or lung disease exclusion criteria: 1. patients with increased intracranial pressure, uncontrolled hypertension, decompensated heart failure, unstable angina, recent myocardial infarction, complicated arrhythmias, pneumothorax, bullae/blebs in the preceding 3 months 2. any pulmonary or lungs disease 3. any neurological conditions other than stroke 4. using medications that could interfere with neuromuscular control or cause drowsiness. 5. severe cognitive function (mini-mental test result \<24) 6. chronic stroke 7. recurrent stroke, brain stem stroke, and aphasia were excluded.
osilodrostat for the treatment of non-cushing's disease cushing's syndrome

Conditions: Cushing's Syndrome

Summary: this is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-cd cs patients. patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.


Eligibility criteria:
inclusion criteria: 1. male and female patients ≥18 years old with diagnosis of cs, except for cd (i.e., an aetiology of adrenal adenoma, adrenocortical carcinoma, adrenal hyperplasia, or ectopic adrenocorticotropic hormone secretion). patients should have a contemporaneously documented diagnosis of cs as per effective guidelines. 2. patients treated with osilodrostat between april 2019 and study start date as part of atu programme or commercialisation. exclusion criteria: 1. patients who participated in a clinical trial anytime during the study period. 2. patients with pseudo-cushing's syndrome, cyclic cs, or iatrogenic cs.

Keywords: endogenous cushing's syndrome cushing's syndrome osilodrostat